Skip to main content
Signal8
Launch Terminal

Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Monopar Therapeutics Inc. logo

Monopar Therapeutics Inc.

NASDAQ:MNPRHealthcare
-2.21%$70.32
AH$70.32+0.00%vs close
Mkt Cap$472M
Float4.85M
O/S6.71M
Vol
$ Vol
RVOL
Inst Own92.7%
SI23.3%
Earnings
Dilution
Monopar Therapeutics Inc. logoNASDAQ:MNPR$70.32-2.21%
Phase Distribution
6 lead-sponsored trials·2 active·0 completed
Phase 13
Phase 2/31
Not applicable2
Status Overview
Active, not recruiting2
Stopped2
Expanded access2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2/3
    Terminated

    Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

    Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet

    Chemoradiotherapy-Induced Severe Oral Mucositis

    Enrollment
    190
    Start
    Feb 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04648020
  • Phase 1
    Terminated

    Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

    Camsirubicin

    Advanced Soft-tissue Sarcoma

    Enrollment
    14
    Start
    Sep 2021
    Primary Completion
    Oct 2023
    Completion
    May 2024
    NCT05043649
  • Phase 1
    Active, not recruiting

    Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

    MNPR-101-DFO*-89Zr

    Solid Tumor, Adult, Bladder Cancer +7

    Enrollment
    12
    Start
    May 2024
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT06337084
  • Phase 1
    Active, not recruiting

    Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

    MNPR-101-PCTA-177Lu

    Solid Tumor, Adult, Bladder Cancer +7

    Enrollment
    12
    Start
    Oct 2024
    Primary Completion
    Jan 2027est.
    Completion
    Feb 2027est.
    NCT06617169
  • Expanded access
    Temporarily not available

    MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

    MNPR-101-DFO*-89Zr

    Cancer, Solid Tumor +1

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06980506
  • Expanded access
    Temporarily not available

    MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

    MNPR-101-PCTA-177Lu

    Cancer, Solid Tumor +4

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06980519
Search ClinicalTrials.gov for “Monopar Therapeutics”